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Catheter ablation has been established as a rhythm control strategy in selected patients with
atrial fibrillation (AF) who have failed or wish to avoid anti-arrhythmic drugs. Uninterrupted oral
anticoagulation with vitamin K antagonists (VKAs) peri-ablation is associated with a lower risk
of thromboembolic and bleeding complications as compared to interrupted oral anticoagulation
and bridging heparin. However, a substantial portion of patients with AF are treated with non-
vitamin K antagonist oral anticoagulants (NOACs). Herein, we perform an in-depth review and
comparison of three recent randomized trials of uninterrupted oral anticoagulation with NOACs
vs VKAs in patients undergoing AF catheter ablation. Furthermore, we report pooled results of
these randomized trials. The pooled incidence of major bleeding was significantly lower with
NOACs as compared to VKAs (2% vs 4.9%, respectively; odds ratio [OR] 0.40; 95% confidence
intervals [CI] 0.16-0.99). Similarly, cardiac tamponade was also reduced in the NOAC group
(0.4% vs 1.5%; OR 0.27; 95% CI 0.07-0.97). Thromboembolic complications were not signifi-
cantly different between groups. Overall, these findings support the 2017 HRS/EHRA/ECAS/
APHRS/SOLAECE expert consensus statement's class I recommendation for uninterrupted
NOAC use in patients undergoing AF catheter ablation.
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1 | INTRODUCTION
Catheter ablation is a safe and effective rhythm control strategy for
selected patients with atrial fibrillation (AF), with worldwide exponen-
tial growth in recent years.1 In the 2017 HRS/EHRA/ECAS/APHRS/
SOLAECE expert consensus statement, catheter ablation received a
class I recommendation in patients with symptomatic, paroxysmal AF,
who have recurrent AF despite anti-arrhythmic drug (AAD) therapy
for maintenance of sinus rhythm. A IIa recommendation was given for
second-line therapy in those with persistent AF. In addition, catheter
ablation received a IIa recommendation in selected patients with
symptomatic paroxysmal or persistent AF before a trial of AAD, that
is, as first-line therapy.2
In patients undergoing AF catheter ablation, periprocedural bleed-
ing and thromboembolic complications are significantly reduced by
Abbreviations: AAD, anti-arrhythmic drug(s); ACE, asymptomatic cerebral
embolism; AF, atrial fibrillation; CI, confidence interval; INR, international nor-
malized ratio; MRI, magnetic resonance imaging; NOAC, non-vitamin K antago-
nist oral anticoagulant(s); TEE, transesophageal echocardiogram; TIA, transient
ischemic attack; VKA, vitamin K antagonist(s).
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uninterrupted anticoagulation with vitamin K antagonists (VKAs) as
compared to bridging heparin.3 The uninterrupted use of non-vitamin
K antagonist oral anticoagulants (NOACs) periablation, in contrast,
was not routinely recommended in guidelines until recently because
of insufficient evidence from randomized studies.4 Over recent years,
however, three randomized trials were published comparing uninter-
rupted anticoagulation with NOACs to VKAs in patients undergoing
catheter ablation for AF: VENTURE-AF,5 RE-CIRCUIT,6 and AXAFA-
AFNET 5.7 This review aims to provide an overview of the evidence
from these randomized trials, and to contrast differences and similari-
ties with regard to study design, patient population, and outcomes.
2 | HISTORICAL PERSPECTIVE
Published in 2014, the COMPARE trial randomized 1584 patients
undergoing radiofrequency catheter ablation for treatment of AF to a
strategy of uninterrupted VKA (on-warfarin) vs warfarin discontinua-
tion 2 to 3 days before the ablation followed by bridging with low-
molecular weight heparin (off-warfarin). There was a greater than
15-fold increase in cerebrovascular thromboembolic events in the off-
warfarin (4.9%) group as compared to uninterrupted VKA (0.3%). Fur-
thermore, bleeding complications were also lower in the on-warfarin
group.3 These findings were consistent with previously published
non-randomized data.8–10
Although the use of uninterrupted VKA is undoubtedly simpler
and more convenient than bridging with heparin, there are a few limi-
tations to this strategy. First, it contrasts with the increasing use of
NOACs for patients with AF, including those undergoing catheter
ablation of AF.11–13 Switching from a NOAC to VKA for the purpose
of a procedure is as disruptive as bridging with heparin, if not more.
Second, with VKA use, the ablation may have to be canceled because
of a supratherapeutic international normalized ratio (INR) on the day
of the procedure. In COMPARE, patients were excluded from enroll-
ment if the INR was >3.5 on the day of the ablation. And third, with a
VKA strategy, it is possible for patients to present for ablation with a
subtherapeutic INR, leading either to cancellation of the procedure or
the performance of catheter ablation with a subtherapeutic INR with
its associated increase in stroke risk.
Considering the benefits of uninterrupted anticoagulation shown
with VKAs and the convenience of NOAC use, observational studies
were published on outcomes of uninterrupted NOACs for periproce-
dural anticoagulation in patients undergoing AF catheter ablation. An
early meta-analysis including 3544 patients primarily from observa-
tional studies compared uninterrupted NOACs to uninterrupted VKAs
in patients undergoing AF catheter ablation and found no difference
in the rates of thromboembolic or bleeding outcomes between
groups.14
The lack of definitive randomized data comparing uninterrupted
anticoagulation strategies, however, led to substantial heterogeneity
in clinical practice. This was confirmed by a survey including electro-
physiologists in 13 European countries and 455 patients undergoing
AF catheter ablation.12 Although approximately 50% of patients
received continuous periprocedural VKAs with a therapeutic INR, only
4% underwent catheter ablation with uninterrupted NOACs. In this
context, three randomized controlled trials were designed and con-
ducted comparing NOACs to VKAs for uninterrupted anticoagulation
in patients undergoing catheter ablation for AF—VENTURE-AF (rivar-
oxaban), RE-CIRCUIT (dabigatran), and AXAFA-AFNET
5 (apixaban).5–7
3 | STUDY DESIGN
VENTURE-AF, RE-CIRCUIT, and AXAFA-AFNET 5 were multicenter,
open label trials. AXAFA-AFNET and VENTURE-AF were conducted
in 49 and 46 sites, respectively, in Europe and the United States. RE-
CIRCUIT involved 104 centers in Japan, Europe, Russia, and North
America.
In AXAFA-AFNET 5, patients were stratified by site and AF type
(paroxysmal, persistent, or long-standing persistent) and then random-
ized in a 1:1 ratio to apixaban 5 mg twice daily (2.5 mg b.i.d. if two of
the three were present: age ≥ 80 years, weight ≤ 60 Kg, or serum
creatinine ≥1.5 mg/dL) or VKA with a goal INR of 2 to 3. Catheter
ablation was performed after at least 30 days of continuous anticoa-
gulation or earlier if a transesophageal echocardiogram (TEE) was per-
formed. In the latter case, after TEE, patients were required to have
either an INR ≥2.0 or a minimum of two apixaban doses in the VKA
and NOAC groups, respectively.
In RE-CIRCUIT, patients were randomized, without stratification,
in a 1:1 ratio to dabigatran 150 mg twice daily or warfarin with dose
adjustment to achieve a target INR of 2.0 to 3.0 (<2.6 in Japanese
sites for patients ≥70 years old). After randomization, all patients were
treated with oral anticoagulation for 4 to 8 weeks pre-ablation to
ensure a stable INR range in those receiving warfarin for at least
4 weeks prior to the ablation. In addition, all patients underwent a
pre-ablation TEE to rule out left atrial thrombi.
In VENTURE-AF, patients were stratified by country and random-
ized in a 1:1 ratio to rivaroxaban 20 mg daily (evening dose given on
the day before ablation) or to VKA with a goal INR of 2.0 to 3.0. In
patients who underwent a TEE, catheter ablation was performed 1 to
7 days after exposure to the study drug. In those who did not have a
TEE, catheter ablation was performed 4 to 5 weeks after
randomization.
All three trials received industry funding and had an independent
steering committee to oversee trial design and conduct. All three trials
also used a blinded adjudication committee for endpoint events. In
addition, an independent data and safety monitoring board was part
of AXAFA-AFNET 5 and RE-CIRCUIT.
4 | PATIENT POPULATION
The inclusion and exclusion criteria were similar between the three tri-
als (Table 1). The three studies included patients with paroxysmal, per-
sistent, or long-standing non-valvular AF. All trials excluded patients
with recent ischemic stroke and those with contra-indications for
anticoagulation. The criteria defining recent stroke was ≤14 days in
AXAFA-AFNET 5; ≤ 1 month in RE-CIRCUIT; and ≤ 6 months in
VENTURE-AF. As a result, a history of prior stroke or transient
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ischemic attack (TIA) was present in 7.4%, 3%, and 1.2%, of the popu-
lation in AXAFA-AFNET 5, RE-CIRCUIT, and VENTURE-AF, respec-
tively.5–7 There were only slight differences in the patient population
between the different studies, as summarized in Table 2. About one-
third of the patients were women. Notably, the average age of the
population was slightly higher in AXAFA-AFNET 5 as compared to the
other two trials. The mean CHA2DS2-VASc score in patients random-
ized to the NOAC group was lower in VENTURE-AF (1.4), as com-
pared to RE-CIRCUIT (2.0) and AXAFA-AFNET 5 (2.4). Hypertension
was nearly universal in AXAFA-AFNET (~90%), whereas the preva-
lence was approximately 50% in the other studies. Similarly, heart fail-
ure was present in one-quarter of the patients in AXAFA-AFNET,
which is about double of the prevalence in RE-CIRCUIT and
VENTURE-AF. AF was paroxysmal in 60%, 67%, and 76% of the pop-
ulation in AXAFA-AFNET 5, RE-CIRCUIT, and VENTURE-AF,
respectively.
5 | PROCEDURAL DATA
In all three studies, patients randomized to the NOAC group received
anticoagulation in an uninterrupted fashion following the approved
posology of each medication, that is, including the morning of (for
twice-daily medications) or the evening prior (for once-daily medica-
tions) to the procedure. In VENTURE-AF, once daily rivaroxaban was
given daily in the evening, and administered post-procedure at least
6 hours following hemostasis. In RE-CIRCUIT, dabigatran was given
on the morning of the procedure, and continued in the evening, with a
minimum delay of 3 hours after sheath removal and hemostasis. In
AXAFA-AFNET 5, apixaban was administered on the morning and
evening of the procedure, though a time frame for resuming apixaban
after ablation or sheath removal was not specified.
VENTURE-AF did not report the number of additional lesion sets
or the proportion of radiofrequency vs cryoablation. In AXAFA-
AFNET 5 and RE-CIRCUIT, about 10% and 20%, respectively, of
patients received other ablation lesions in addition to pulmonary vein
isolation. Radiofrequency was the predominant energy source, though
roughly one-quarter of patients underwent cryoablation in both
AXAFA-AFNET 5 and RE-CIRCUIT.
Unfractionated heparin was administered before or immediately
after transseptal puncture. The activated clotting time (ACT) goal was
>300 seconds in AXAFA-AFNET 5 and RE-CIRCUIT, and 300 to
400 seconds in VENTURE-AF. As shown in Table 2, the mean intra-
procedural ACT was lower in the NOAC group as compared to VKA-
TABLE 1 Inclusion and exclusion criteria
AXAFA-AFNET 5 RE-CIRCUIT VENTURE-AF
Inclusion criteria
• Age ≥ 18 years • Age ≥ 18 years
• Age ≥ 18 years
• Paroxysmal, persistent, or
long-standing NVAF
• Paroxysmal, persistent, or
long-standing NVAF
• Paroxysmal, persistent, or long-standing NVAF
• CHADS2 ≥ 1 • At least one episode of
documented AF in <24 months
• CHADS2 or CHA2DS2-VASc score ≥ 1
Exclusion criteria • Valvular AFa • Valvular AFa • Valvular AFa
• Life expectancy <1 year • Reversible cause to AF • Reversible cause to AF
• LA size ≥60 mm • MI <2 months
• Stroke <14 days • OAC contra-indication • CABG<6 months
• Concomitant use of strong
cytochrome P450 inhibitors
• CrCl<30 mL/min • LVEF ≤40%, NYHA class III or IV, or ICD
• Stroke/major surgery <1 month
• Previous organ transplantation • LA >55 mm or thrombus
• OAC contra-indication
• CrCl ≤50 mL/min
• Previous ablation for AF • History of intracranial,
intraocular, spinal,
retroperitoneal, or spontaneous
intra-articular bleed
• ≥moderate hepatic disease
• Indication for DAPT • Stroke/TIA or major surgery <6 months
• Contraindication to OAC
• GI or major bleed <1 month • Major bleed or thrombo-embolism <12 months
• LA thrombi <3 months • Bleeding diathesis • Need for high-intensity antiplatelet therapy
• eGFR<15 mL/min or need
for RRT
• Hb < 10 g/dL
• Platelets<100 × 109/L • Premenopausal women not on contraception
• Malignancy ≤6 months• Premenopausal women not on
contraception • Active liver disease
• Premenopausal women not on
contraception
Abbreviations: AF, atrial fibrillation; CABG, coronary artery bypass grafting surgery; CrCl, creatinine clearance; DAPT, dual antiplatelet therapy; eGFR, esti-
mated glomerular filtration rate; GI, gastrointestinal; Hb, hemoglobin; LA, left atrium; LVEF, left ventricular ejection fraction; MI, myocardial infarction;
NVAF, non-valvular atrial fibrillation; NYHA, New York Heart Association; OAC, oral anticoagulation; RRT, renal replacement therapy.
a In AXAFA-AFNET 5, defined as absence of severe mitral stenosis or mechanical heart valve; in RE-CIRCUIT, defined as absence of rheumatic mitral ste-
nosis, mechanical or bioprosthetic heart valve, hemodynamically severe valve disease, or mitral valve repair; in VENTURE-AF, defined as absence of a
prosthetic heart valve (annuloplasty with or without prosthetic ring, and valvuloplasty were allowed) and hemodynamically significant mitral stenosis.
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treated patients in all three studies. In the VENTURE-AF trial, the total
heparin dose needed to achieve the goal ACT was higher with rivarox-
aban (13 871  6516 units) compared to VKA treatment
(10 964  5912 units). Post-ablation, anticoagulation with the study
drug was mandatory for 3 months in AXAFA-AFNET 5, 8 weeks in
RE-CIRCUIT, and 30 days in VENTURE-AF. Thereafter, anticoagula-
tion management was at the discretion of the treating physicians.
6 | ENDPOINTS AND SAMPLE SIZES
There were important differences in the study design between trials
with regard to endpoints (Table 3). AXAFA-AFNET 5 planned to enroll
650 patients to demonstrate non-inferiority of the uninterrupted
NOAC strategy at a pre-specified margin of 7.5% with regard to the
primary composite endpoint of all-cause mortality, stroke, or major
bleeding per Bleeding Academic Research Consortium (BARC 2 or
higher) criteria. Of note, this margin was wide, as physicians and
patients may not consider the uninterrupted NOAC strategy as an
acceptable alternative to uninterrupted VKA if it were associated with
an absolute risk increase of up to 7.5% in the composite endpoint of
death, stroke, or major bleeding. Furthermore, the power calculation
was based on an anticipated overall event rate of 17%, whereas the
results showed a much smaller event rate of 7.1%. AXAFA-AFNET
5 was unique in performing a systematic evaluation of quality-of-life
and cognitive function at baseline and during follow-up. In addition,
25 out of the 49 centers participated in a magnetic resonance imaging
(MRI)-substudy protocol, where all patients underwent a brain MRI
within 48 hours of the ablation procedure to detect acute brain
lesions.
RE-CIRCUIT and VENTURE-AF, however, compared the two
uninterrupted anticoagulation strategies for the primary endpoint of
major bleeding. Both studies were designed as exploratory analyses
only because the sample sizes required to demonstrate non-inferiority
in bleeding endpoints were considered to be prohibitive and the
absence of a commonly accepted non-inferiority margin. VENTURE-
AF planned on enrolling 250 patients to demonstrate a clinically rele-
vant difference between groups, if any. In RE-CIRCUIT, assuming a
major bleeding rate between 0.59% and 4.55% in both groups and a
sample size of 580 patients, power calculations estimated the upper
limit of the confidence interval (CI) for major bleeding to be between
2.48% and 4.98%. All three studies reported major bleeding outcomes
using International Society on Thrombosis and Hemostasis (ISTH) cri-
teria; AXAFA-AFNET 5 and VENTURE-AF reported additional criteria
for major bleeding (Table 3).
TABLE 2 Baseline and procedural characteristics
AXAFA-AFNET 5 RE-CIRCUIT VENTURE-AF
NOAC vs. VKA NOAC vs. VKA NOAC vs VKA
Number of patients 318/315 317/318 124/124
Age (years), mean or median 64/64 59.1/59.3 58.6/60.5
Age ≥ 75 years 8.8%/8.9% NR 4%/8.1%
Female gender 31%/35% 27.4%/23% 31.6%/27.4%
BMI, kg/m2, mean or median 28.4/28.2 28.5/28.8 29.8/28.9
CHA2DS2-VASc, mean 2.4/2.4 2/2.2 1.5/1.7
Hypertension 89%/91.4% 52.4%/55.7% 47.6%/46%
Congestive heart failure 24.5%/22.9% 9.8%/10.7% 9.7%/7.3%
Diabetes mellitus 12.9%/11.1% 9.5%/10.7% 6.5%/11.3%
Prior stroke or TIA 7.5%/7.3% 3.2%/2.8% 0%/2.4%
Coronary artery disease 12.3%/12.1% 10.1%/15.1% NR
Beta-blocker 72.3%/70.2% 57.7%/60.4% 52.4%/49.2%
Paroxysmal AF 59.4%/56.5% 67.2%/68.9% 76.6%/70.2%
Persistent AF 40.6%/43.5% 32.8% / 31.2% 23.4%/29.8%
Prior catheter ablation 0% NR 8.9%/8.9%
TEE prior to ablation 84.6% 100% NR
Other lesion sets in addition to PVI 9.1% 21% NR
Cryoablation 28.9% 28% NR
Estimated NOAC compliancea 97% 97.6% 99.9%
INR, time in therapeutic rangeb 84% 85.7% 79.8%
INR on day of ablation NR NR 65%, 1.8-3.2
ACT (seconds), mean or median 310/348 330/340 302/332
Abbreviations: ACT, activated clotted time; AF, atrial fibrillation; BMI, body mass index; INR, International Normalized Ratio; NOAC, novel oral anticoagu-
lant; NR, not reported; PVI, pulmonary vein isolation; TIA, transient ischemic attack; TEE, transesophageal echocardiogram; VKA, vitamin K antagonist.
a Compliance reported as follows: in AXAFA-AFNET 5, by the % of patients who took all or all but one apixaban doses per week; in RE-CIRCUIT, by the %
of patients who took between 80% to 120% of the expected dose; in VENTURE-AF, by % of patients with documented compliance of at least 80% as
determined by physician assessment or patient interview.
b The time in therapeutic range was calculated by the Rosendaal method in AXAFA-AFNET 5 and RE-CIRCUIT, but not specified in VENTURE-AF. Median
reported in AXAFA-AFNET and RE-CIRCUIT; mean vs. median not specified in VENTURE-AF.
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7 | OUTCOMES
7.1 | Major bleeding
In AXAFA-AFNET 5, bleeding with apixaban was comparable to the
VKA group according to BARC 2 to 5 criteria (6.2% vs 7.9%, respec-
tively), thrombolysis in myocardial infarction (TIMI) major bleeding cri-
teria (0.3% vs 1%, respectively), and ISTH criteria (3.1% vs 4.4%,
respectively) (Table 3). In VENTURE-AF, there was only one major
bleeding event in the VKA group vs none in the NOAC group.
In RE-CIRCUIT, ISTH-defined major bleeding outcomes were sig-
nificantly reduced by uninterrupted dabigatran (1.6%) as compared to
uninterrupted warfarin (6.9%), with a hazard ratio of 0.22 (95% CI
0.08-0.59). The mean intraprocedural ACT among patients who had
major bleeding was higher in the dabigatran group as compared to the
warfarin group (374 vs 314 seconds, respectively). There was no dif-
ference between bleeding rates in patients who received dabigatran
within 4 hours vs between 4 and 8 hours before ablation. Similarly, in
the VKA group, the INR at the time of ablation was not different
between the patients with (2.4) vs without (2.3) major bleeding.
A pooled analysis of the three studies (Figure 1A) shows a lower
rate of ISTH-defined major bleeding with NOAC (2%) vs VKA (4.9%)
(OR 0.40; 95% CI 0.16-0.99; P = 0.05). The incidence of cardiac tam-
ponade was also lower with NOAC vs VKA therapy (Figure 1B; OR
0.27; 95% CI 0.07-0.97; P = 0.04). Patients with cardiac tamponade
(n = 14) were managed with pericardiocentesis (n = 14) and prot-
amine administration (n = 12). Only 2 of the 11 patients with tampo-
nade in the VKA group required reversal with prothrombin complex
concentrate. No patient required surgical intervention for tamponade
in either group. Idarucizumab, a specific reversal agent for dabigatran,
was not used to reverse any major bleeding episode in the RE-
CIRCUIT trial.
7.2 | Mortality and thromboembolic outcomes
In AXAFA-AFNET 5, one patient in the VKA group died from intrace-
rebral hemorrhage and another one in the NOAC group died from an
unknown cause. In VENTURE-AF, there was a sudden death in the
VKA group of unknown cause. No patient died in RE-CIRCUIT.
Strokes or TIA were also infrequent: two patients receiving apixaban
in AXAFA-AFNET 5, and one patient treated with warfarin in both
RE-CIRCUIT and VENTURE-AF. The timing of strokes or TIA in refer-
ence to the AF catheter ablation was as follows: same day (1 patient),
within the same hospitalization (1 patient), 27 days post-procedure
(1 patient), and not specified in one patient.
At least mild cognitive dysfunction was seen in nearly one-third
of patients enrolled in AXAFA-AFNET 5 at baseline. Though there
was a 7% absolute reduction in the number of patients with cognitive
dysfunction at follow-up after ablation, there was no significant differ-
ence in cognitive function between groups. Similarly, in their MRI-
substudy including 335 patients, acute MRI lesions post-ablation were
seen in 27% of apixaban-treated patients vs 25% of those who were
randomized to VKAs (P = 0.63).
7.3 | Composite outcomes
The primary endpoint of all-cause death, stroke, or major bleeding
was not significantly different between apixaban- (6.9%) and VKA-
(7.3%) treated patients in the AXAFA-AFNET 5 trial, meeting the
pre-specified non-inferiority criteria (P < 0.01 for non-inferiority).7 In
RE-CIRCUIT, the composite of thromboembolic events and major
bleeding was lower in the dabigatran group (1.6%) vs the warfarin
group (7.2%), which was driven entirely by major bleeding because no
strokes or deaths were observed in the dabigatran group.6 In
VENTURE-AF, the composite of thromboembolic events (stroke, sys-
temic embolism, myocardial infarction, and vascular death) occurred in
TABLE 3 Outcomes and endpoint definitions
AXAFA-AFNET 5 RE-CIRCUIT VENTURE-AF
Primary
outcome
All-cause mortality, stroke, or major
bleeding (BARC ≥2)
ISTH major bleeding events Major bleeding events
Analysis Modified ITT, all randomized
patients who underwent CA
Ablation set, all patients who
received study drug and
underwent CA
PPA, all patients who received study drug and
underwent CA
Secondary
outcomes
Length of stay; all bleeding events;
tamponade; need for transfusion;
quality of life; cognitive function;
and prevalence of MRI-detected
acute brain lesions
Composite of stroke, TIA, and
systemic embolism; minor
bleeding events; and
composite of major bleeding
and thromboembolic events
Composite (and individual) events of ischemic stroke,
systemic embolism, myocardial infarction, and
vascular death; other bleeding events;
procedure-attributable adverse events
Follow-up 3 months 8 weeks 30 days
Major bleeding
definitions
BARC, ISTH, TIMI ISTH GUSTO, ISTH, TIMI
Abbreviations: BARC, Bleeding Academic Research Consortium; CA, catheter ablation; GUSTO, Global Use of Strategies to Open Occluded Arteries; ISTH,
International Society on Thrombosis and Hemostasis; ITT, intention-to-treat; PPA, per protocol analysis; TIA, transient ischemic attack; TIMI, thrombolysis
in myocardial infarction.
• BARC—type 2: any overt, actionable sign of hemorrhage requiring non-surgical evaluation by a healthcare professional or hospitalization; type 3a: overt
bleeding requiring transfusion or associated with hemoglobin drop of 3–5 g/dL; type 3b: cardiac tamponade or bleeding requiring surgery, vasoactive
agents, or associated with a hemoglobin drop ≥5 g/dL; type 3c: intracranial, intraspinal, or intraocular bleed; type 4: CABG-related bleeding; type 5: fatal
bleeding.
• GUSTO severe or life-threatening—intracerebral hemorrhage or bleeding resulting in hemodynamic compromise requiring treatment.
• ISTH major bleeding—fatal bleeding, symptomatic bleeding in a critical area or organ (intracranial, intraspinal, intraocular, retroperitoneal, intra-articular,
pericardial, or intramuscular), or bleeding associated with a hemoglobin drop of ≥2 g/dL or requiring transfusion of ≥2 red cell units.
• TIMI major bleeding—intracranial bleeding, clinically overt hemorrhage associated with a hemoglobin drop ≥5 g/dL, or fatal bleeding.
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2 patients treated with VKAs and in none of the rivaroxaban-treated
patients.5 The pooled composite endpoint of mortality, stroke or TIA,
and major bleeding between the three studies is reported in
Figure 1C, showing no significant difference between groups
(OR 0.38; 95% CI 0.11-1.27; P = 0.11).
8 | DISCUSSION
These results attest to the efficacy and safety of an uninterrupted
NOAC strategy in patients undergoing AF ablation. The lower numeri-
cal incidence of all bleeding endpoints in the NOAC group is reassur-
ing to physicians and patients who wish to avoid switching from a
NOAC to warfarin merely for catheter ablation.
Of note, the low incidence of strokes or TIA in these three random-
ized trials (4/1516; 0.2%) is similar to reports including observational
data, which may be more reflective of real-world practice, and substan-
tially lower than the incidence of stroke in studies of interrupted oral
anticoagulation. In a meta-analysis of nearly 5000 patients, the inci-
dence of stroke was 0.08% and 0.16% with uninterrupted NOACs and
VKAs, respectively.15 In the COMPARE trial, nearly 5% of patients ran-
domized to warfarin discontinuation with heparin bridging had peripro-
cedural stroke or TIA.3 Similarly, observational data of NOAC
interruption even for less than 24 to 48 hours has been associated with
a substantially higher incidence of stroke or TIA (0.5-2%).16,17
The recently published AEIOU trial randomized 300 patients
undergoing catheter ablation for AF to a strategy of holding one pre-
procedural dose of apixaban (minimally interrupted) vs uninterrupted
anticoagulation with apixaban.18 There was one TIA in each group,
and no stroke or systemic embolism with either strategy. The inci-
dence of major bleeding was similar between the minimally inter-
rupted (2.1%) and uninterrupted (1.3%) strategies. This approach
FIGURE 1 The incidence of major bleeding (A) and cardiac tamponade (B) were significantly lower in the non-vitamin K antagonist oral
anticoagulants group as compared to vitamin K antagonists. No significant difference between groups was noted in the composite outcome of
mortality, stroke or transient ischemic attack, and major bleeding
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should be studied further before widely adopted. Until then, clinicians
should consider using uninterrupted anticoagulation with NOACs on
the basis of the three randomized trials here reported, with a lower
incidence of major bleeding compared to uninterrupted VKAs and a
lower incidence of thromboembolism compared to historical controls
of interrupted anticoagulation.
The incidence of asymptomatic cerebral embolism (ACE) assessed
by routine imaging following catheter ablation for AF varies between
2 to 41% in the literature, depending on the definition of ACE and imag-
ing criteria.19 In AXAFA-AFNET 5, 335 patients underwent brain MRI
within 3 to 48 hours of ablation including diffusion-weighted imaging
and fluid-attenuated inversion recovery methodology. Approximately
one-quarter of patients had an acute brain lesion detected by MRI
within 48 hours of catheter ablation, despite a strategy of strict uninter-
rupted anticoagulation.7 These findings suggest that some embolic
mechanisms may not be preventable with anti-thrombotic therapy, such
as air embolism, thermal thrombus related to radiofrequency delivery,
or debris from ablation lesions. Of note, in the FIRE and ICE trial, the
ablation method did not affect the incidence of stroke or TIA among
762 patients randomized to cryoballoon or radiofrequency ablation. In
addition, though the duration of pre-procedure interruption of anticoa-
gulation was not specified, the incidence of stroke or TIA (0.5%) in FIRE
and ICE was also numerically higher than the cumulative incidence with
uninterrupted anticoagulation (0.2%), as reported here.20
With regards to the choice of specific NOAC, two separate drug
classes are available. Dabigatran etexilate is a prodrug, converted to
the active form in plasma and in the liver. It is a competitive, direct
inhibitor of free thrombin and fibrin-bound thrombin, preventing the
conversion of fibrinogen to fibrin and therefore clot formation. In con-
trast, rivaroxaban and apixaban are direct, potent and selective com-
petitive inhibitors of factor Xa. Head-to-head comparisons between
thrombin and factor Xa inhibitors, however, are lacking. Nevertheless,
factors such as patient age, renal function, and drug interactions can
guide individualized treatment.
There is yet another direct factor Xa inhibitor being studied for
uninterrupted anticoagulation in patients undergoing AF catheter
ablation. The ongoing Edoxaban Compared with VKA in Subjects
Undergoing Catheter Ablation of Non-valvular Atrial Fibrillation
(ELIMINATE-AF) randomized trial plans to enroll 560 patients to com-
pare uninterrupted edoxaban vs VKA for the primary endpoint of all-
cause death, stroke, and major bleeding.21
The 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus
statement on catheter and surgical ablation of AF supports uninter-
rupted anticoagulation before catheter ablation for AF in patients
treated with warfarin (class I, level of evidence - LOE - A), dabigatran
(class I, LOE A), rivaroxaban (class I, LOE B-randomized), and apixaban
(class IIa, LOE B-non-randomized).2 Of note, these guidelines pre-
ceded the publication of AXAFA-AFNET 5, which has added random-
ized evidence supporting uninterrupted anticoagulation with apixaban
at the time of AF catheter ablation.7
Though the need for hemostatic surgical intervention was not
reported in any of the patients receiving NOACs, major bleeding still
occurred in 2% of those patients. Therefore, electrophysiologists may
consider the use of NOACs with specific reversal agents when plan-
ning catheter ablation. At present, only dabigatran has a widely
available direct reversal agent, idarucizumab.22 A reversal agent for
factor Xa inhibitors, andexanet alpha, has been recently approved in
the US; however, it is not yet widely available.23
Finally, the absence of head-to-head comparison and the differ-
ent risk profiles between the three trials do not allow for a direct com-
parison between factor IIa (ie, dabigatran) over factor Xa inhibitors.
However, dabigatran was the only drug which showed a significantly
decreased incidence of major bleeding as compared to VKA in
patients undergoing catheter ablation for AF on uninterrupted
anticoagulation.
9 | CONCLUSION
In summary, data from three randomized trials including more than
1500 patients attest to the safety and efficacy of uninterrupted antic-
oagulation with NOACs in patients undergoing catheter ablation for
AF. Though the trials had different primary endpoints and objectives,
overall findings were consistent between studies. Uninterrupted
NOAC therapy was associated with a low incidence of major bleeding
(2%), cardiac tamponade (0.4%), and clinical cerebrovascular events
(0.2%). These findings support the use of uninterrupted NOACs at the
time of AF ablation, as recommended by the 2017 HRS/EHRA/ECAS/
APHRS/SOLAECE expert consensus statement on catheter and surgi-
cal ablation of AF.
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